Study suggests lorazepam may cut repeat urethral blockage in cats: full analysis

A newly indexed JAVMA study reports that lorazepam reduced recurrence of urethral obstruction in male cats in a prospective, randomized, double-blinded, placebo-controlled trial, giving clinicians fresh evidence in one of small-animal emergency medicine’s most frustrating repeat-presentation problems. According to the study abstract, investigators Alexa Splittstoesser, Jessica Kerley, and Jody Lulich enrolled 80 client-owned male cats presenting with urethral obstruction at a university teaching hospital from 2021 through 2025, focusing on first-time cases and excluding cats with urolithiasis or urinary tract infection. (vetlit.org)

That’s notable because recurrence prevention after feline urethral obstruction has long been a gray zone. Urethral obstruction is a life-threatening emergency in cats, especially males, and rapid intervention is essential because complete obstruction can quickly lead to severe electrolyte derangements and death. Yet while clinicians routinely use catheterization, fluids, analgesia, and close monitoring, the evidence base for post-discharge drug strategies has been uneven. (vet.cornell.edu)

Earlier work helps explain why this study stands out. Prior literature has described urethral spasm as one contributor to post-obstructive difficulty voiding, which helped drive use of antispasmodic or smooth-muscle–targeting medications in practice. But randomized evidence for prazosin, one of the better-known options, has been undercut by studies showing no benefit or even increased recurrence risk in some populations. That left clinicians with a common problem, plausible mechanisms, and limited confidence in the available pharmacologic tools. (dvm360.com)

The lorazepam finding is therefore clinically interesting on two levels. First, it suggests a benzodiazepine may have a practical role after hospitalization in selected cats with first-time obstruction. Second, it points attention back to the stress, arousal, and functional-outflow components of feline lower urinary tract disease, not just mechanical obstruction. Cornell’s feline lower urinary tract disease guidance notes that many cats with lower urinary tract disease experience recurrence, while obstruction itself remains the most dangerous presentation. (vet.cornell.edu)

There wasn’t much public expert reaction available at the time of search, but the broader pharmacology is relevant. A feline behavior medicine review describes lorazepam as a benzodiazepine used in cats for anxiety, fear, and panic, with oral dosing commonly cited at 0.125 to 0.25 mg/cat every 12 to 24 hours, and notes that lorazepam lacks active intermediate metabolites, which may make it a comparatively usable option in cats. The same review also reminds clinicians to expect possible sedation, ataxia, muscle relaxation, increased appetite, or paradoxical excitation. Those considerations will matter when practitioners weigh any recurrence benefit against discharge safety, client compliance, and the cat’s home environment. (journals.sagepub.com)

Why it matters: For veterinary professionals, the biggest implication is that post-obstruction management may be moving toward more evidence-based medication choices rather than habit or anecdote. If the full paper shows a meaningful absolute reduction in recurrence without problematic adverse effects, lorazepam could become part of discharge planning for some first-time obstructed male cats, particularly where stress-related lower urinary tract signs are part of the picture. It would also reinforce the need to distinguish cats with idiopathic or functional obstruction from those with stones or infection, since this study excluded those groups. (vetlit.org)

Just as important, this study may reshape conversations with pet parents. Reobstruction is one of the costliest and most distressing outcomes after an initial hospitalization, and anything that lowers that risk could affect recheck planning, medication counseling, and expectations for the first days after discharge. Still, lorazepam would be an adjunct, not a substitute, for standard emergency care, catheter management, analgesia, diet and environmental review, and clear instructions to return immediately if urination stops or straining returns. (vet.cornell.edu)

What to watch: The next key step is publication of the full article details, especially recurrence rates, timing of benefit, dosing protocol, adverse events, and whether the effect is strong enough to influence emergency and internal medicine protocols more broadly. Given the mixed history of post-obstruction drug therapy in cats, clinicians will likely want replication, or at least close scrutiny, before lorazepam becomes routine. (vetlit.org)